ArticleBMC cancer2026
Disease status stratification individualizes radioiodine therapy for differentiated thyroid cancer: a prospective, multicenter, real-world study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundRecurrence risk stratification system-guided radioiodine (131I) therapy of differentiated thyroid cancer (DTC) has fallen into dilemma due to its poor feasibility and insufficient justification.
methodsSubjects referred for 131I therapy were consecutively labeled with no evidence of disease, unexplained hyperthyroglobulinemia, or known disease based on stimulated serum thyroglobulin, radioiodine uptake, and medical imaging, and then assigned to radioiodine remnant ablation (RRA), radioiodine adjuvant treatment (RAT), or radioiodine oncolytic treatment (ROT) group, respectively. The primary endpoints were disease-free survival (DFS) for the RRA and RAT cohorts and progression-free survival (PFS) and overall survival (OS) for the ROT cohort. Secondary endpoints included success rate in the RRA cohort, response classification in all cohorts, and biochemical and structural responses in the ROT cohort.
resultsIn the RRA and RAT cohorts, the 5-year DFS rates were 93.28% and 76.02%, respectively. In the ROT cohort, the 5-year PFS and OS rates were 72.23% and 99.01%, respectively. In the RRA cohort, an 85.06% success rate was achieved, with excellent response (ER), indeterminate response (IR), biochemical incomplete response (BIR) and structural/functional incomplete response (S/FIR) rates of 77.92%, 15.58%, 3.9%, and 2.6%, respectively. In RAT cohort, ER, IR, BIR and S/FIR rates were 16.42%, 26.87%, 33.83%, and 22.89%, respectively. In the ROT cohort, ER, IR, BIR, and S/FIR rates were 2.5%, 3.33%, 8.33%, and 85.83%, respectively, with biochemical remission rate of 69.49% and structural disease control rate of 96.15%.
conclusionThis prospective, multicenter, real-world study justified postoperative disease status stratification as a feasible guidance for individualizing 131I therapy of DTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.